Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. - Wikidata - awgldk - TriplyDB

Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo.

Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo.

http://www.wikidata.org/entity/Q34435699

about

Dexamethasone causes sustained expression of mitogen-activated protein kinase (MAPK) phosphatase 1 and phosphatase-mediated inhibition of MAPK p38.A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promoters Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects Discovery of Compound A--a selective activator of the glucocorticoid receptor with anti-inflammatory and anti-cancer activity Selective glucocorticoid receptor-activating adjuvant therapy in cancer treatments Glucocorticoids inhibit lipopolysaccharide-induced up-regulation of arginase in rat alveolar macrophages Evaluation of the selective glucocorticoid receptor agonist compound A for ototoxic effects Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics.Glucocorticoids antagonize AP-1 by inhibiting the Activation/phosphorylation of JNK without affecting its subcellular distribution.Transcriptional potencies of inhaled glucocorticoids.Crosstalk in inflammation: the interplay of glucocorticoid receptor-based mechanisms and kinases and phosphatases Minireview: latest perspectives on antiinflammatory actions of glucocorticoids.Ginsenoside Rh1 potentiates dexamethasone's anti-inflammatory effects for chronic inflammatory disease by reversing dexamethasone-induced resistance.Molecular genetic analysis of glucocorticoid signaling using the Cre/loxP system.Molecular mechanisms of glucocorticoid action: what is important?New perspectives in asthma treatment.New approaches to topical therapy.A fully dissociated compound of plant origin for inflammatory gene repression Noncanonical mechanisms to regulate nuclear receptor signaling.Molecular mechanisms of corticosteroids in allergic diseases.Glucocorticoid-targeted therapies for the treatment of rheumatoid arthritis.Bone protection by estrens occurs through non-tissue-selective activation of the androgen receptor.Antiinflammatory glucocorticoid receptor ligand with reduced side effects exhibits an altered protein-protein interaction profile.Rapid nontranscriptional activation of endothelial nitric oxide synthase mediates increased cerebral blood flow and stroke protection by corticosteroids.Advances in glucocorticoid-induced osteoporosis The glucocorticoid RU24858 does not distinguish between transrepression and transactivation in primary human eosinophils.Glucocorticoid resistance in childhood leukaemia: mechanisms and modulation.Nontranscriptional actions of the glucocorticoid receptor.Cell specific effects of glucocorticoid treatment on the NF-kappaBp65/IkappaBalpha system in patients with Crohn's disease How corticosteroids control inflammation: Quintiles Prize Lecture 2005 Involvement of simultaneous multiple transcription factor expression, including cAMP responsive element binding protein and OCT-1, for synovial cell outgrowth in patients with rheumatoid arthritis Glucocorticoids repress NF-kappaB-driven genes by disturbing the interaction of p65 with the basal transcription machinery, irrespective of coactivator levels in the cell Clinical trials for cytoprotection in stroke.The possible separation of 12-O-tetradecanoylphorbol-13-acetate-induced skin inflammation and hyperplasia by compound A.Dexamethasone and RU24858 Induce Survival and Growth Factor Receptor Bound Protein 2, Leukotriene B4 Receptor 1 and Annexin-1 Expression in Primary Human Neutrophils.Glucocorticoids for human skin: new aspects of the mechanism of action.Pharmacokinetic/pharmacodynamic evaluation of inhalation drugs: application to targeted pulmonary delivery systems.Insight into the molecular mechanisms of glucocorticoid receptor action promotes identification of novel ligands with an improved therapeutic index.GR SUMOylation and formation of an SUMO-SMRT/NCoR1-HDAC3 repressing complex is mandatory for GC-induced IR nGRE-mediated transrepression Dexamethasone-mediated changes in adipose triacylglycerol metabolism are exaggerated, not diminished, in the absence of a functional GR dimerization domain.

P2860

Q24537701-827964ED-960F-428C-A51D-334127704060 Q24559978-4163A2D6-B608-4296-B508-7F87B1457AD3 Q24630458-9D0E6A81-4963-47CB-A117-E5CCAEA4C280 Q26782111-69FBEE6B-46D3-4AB2-A8F5-32645F09C7B4 Q28078896-56CDE22F-A347-47E8-B0B0-0D8D2193394A Q28566905-2D082846-D1E2-4542-9F93-AC4E00C48BD2 Q30382813-E5EE37FD-38CF-43FE-B355-25BB8D5E80B2 Q30418832-4444C9AE-5970-48CF-8054-002D01B6D3FF Q30918621-709DE212-FC81-4B93-B707-2E695DC8122F Q31409970-B0A1165A-BA8F-4966-9643-F60B2E94B971 Q33636430-38403D4F-8C59-4C7F-B9CA-FAA33F9EF717 Q33670499-5A4DB1F4-1BD9-41E7-8F32-D015982F0FDE Q33767092-ACD915AF-DDDD-4417-86A9-2BC00DF0FA46 Q33925125-8A39C063-EA98-4F11-8AD9-E59B16AABF90 Q33944529-B85468D8-7328-4A20-8340-C12AA26FD8C4 Q33987222-3AF2E02D-CA5A-4B40-8B38-08C2182D82AB Q34106948-EF9654B6-B893-45DB-A81A-878DF6BB5EF0 Q34115914-422D5A97-B76E-4411-9C94-3B02E660491F Q34338685-8A72EE6A-FF1E-4945-90D0-26F8261AA6A5 Q34383896-849D152F-CA6F-4A40-AB65-49F1381A4AD8 Q34548430-F42BC1C7-EF52-4240-9EEB-E455AD05DC9C Q34563775-FAB57EA8-EFF9-4496-B9CC-10A009108517 Q34717142-44F8E39F-0A9A-495A-899A-B7FD45A1D5FF Q34816365-016B6CDD-265B-448B-8030-907BADC7FC60 Q34975913-5B0668DA-380A-417C-949D-ACA792F9624B Q35016058-1A4AF183-C4E9-4D96-ADA4-73FFFA8B96B5 Q35089181-A971BFAA-D1D2-4664-872B-58B3C2475EE1 Q35102215-4913CF72-E610-4F49-8554-12BDD3908A68 Q35357667-B8111C7C-5B9D-468F-A1B9-FB939CC5F1FD Q35545886-F2922D28-4580-4DCA-801A-45D135B3D3A3 Q35548076-F44466F1-8ECF-481E-954A-51FA447FC83E Q35666145-CE82783F-25C4-42D3-96CE-6469646C4044 Q36045223-A463430C-E415-4139-BF7A-DD4D742010CE Q36078315-9C34D4F5-1B99-48BA-A7D7-09C87CBF553C Q36093245-723251A4-B801-45BB-BDCE-63514C9D0F04 Q36129596-6B1CE2BA-1825-41AA-B957-5A9EAE69E9A7 Q36316793-D53B5870-F2FD-478E-AC60-5541CBA38B1C Q36536770-1E3CAFF2-BA9D-4F63-85AB-BECB019B6D78 Q36563336-9FE6C399-C10D-43B2-ABE7-7232947F9121 Q36699512-481CA53E-34AB-491E-A1C6-D9BB1F75993B

P2860

Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo.

http://www.wikidata.org/entity/Q34435699

description

1997 nî lūn-bûn

@nan

1997 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

name

Synthetic glucocorticoids that ...... inflammatory activity in vivo.

@ast

Synthetic glucocorticoids that ...... inflammatory activity in vivo.

@en

Synthetic glucocorticoids that ...... inflammatory activity in vivo.

@nl

type

label

Synthetic glucocorticoids that ...... inflammatory activity in vivo.

@ast

Synthetic glucocorticoids that ...... inflammatory activity in vivo.

@en

Synthetic glucocorticoids that ...... inflammatory activity in vivo.

@nl

prefLabel

Synthetic glucocorticoids that ...... inflammatory activity in vivo.

@ast

Synthetic glucocorticoids that ...... inflammatory activity in vivo.

@en

Synthetic glucocorticoids that ...... inflammatory activity in vivo.

@nl

P1433

Q34435699-95F26FA3-662B-49CE-9D9E-227A572FBD97

P1476

Q34435699-5A6F0DDF-2C2D-48C4-AAF3-A1C185152A5F

P2093

Q34435699-089BF200-6A96-4FC5-BFC2-42A37D0EB6EB

Q34435699-177FB283-1B39-4D52-BC9E-64CEA18B998B

Q34435699-300281DD-5AFB-4EB1-A8BF-F0E1B0E01AA9

Q34435699-6A506215-B9E6-49F5-AE16-6213DAC2FD6C

Q34435699-9106922F-7F81-499B-A62A-DAC7E3DD0BA9

Q34435699-9DFAFDAC-98DF-4F97-86E8-2CF4DB1E88A6

Q34435699-A4A4BBC7-7C35-4762-9C2F-E954BC0AC98C

Q34435699-C0FC811C-C412-4B98-9C1D-B74B9E1F1F29

P304

Q34435699-F970F3E0-1588-47B0-89D8-BB66D4A558B8

P31

Q34435699-E6A5879D-1D07-40E6-BDE5-F6848A910C45

P356

Q34435699-2B2F8768-DFF9-4A17-B624-06320E02275D

P433

Q34435699-55443230-C4A9-4A87-BAF0-2C7A39ECAF63

P478

Q34435699-1CBBC2F3-26C8-4AC6-8FC9-00ACCC30154A

P577

Q34435699-5F6C24AF-72B1-4AF0-8A9E-A5C5F9FBEAAD

P5875

Q34435699-44D5A9D2-A564-4939-9ACE-68DA944A244E

P698

Q34435699-C5AB8962-A3F6-4A9A-BE71-D5CC2C5372A1

P356

P1433

Molecular Endocrinology

P1476

Synthetic glucocorticoids that ...... inflammatory activity in vivo.

@en

P2093

Choquart A

http://www.w3.org/2001/XMLSchema#string

Dupont S

http://www.w3.org/2001/XMLSchema#string

Garcia T

http://www.w3.org/2001/XMLSchema#string

Gronemeyer H

http://www.w3.org/2001/XMLSchema#string

Marchandeau C

http://www.w3.org/2001/XMLSchema#string

Petit F

http://www.w3.org/2001/XMLSchema#string

Resche-Rigon M

http://www.w3.org/2001/XMLSchema#string

Vayssière BM

http://www.w3.org/2001/XMLSchema#string

P304

1245-1255

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1210/ME.11.9.1245

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P577

1997-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

13961540

http://www.w3.org/2001/XMLSchema#string

P698

9259316

http://www.w3.org/2001/XMLSchema#string